FLT3 and leukemia: FLT3 and JAK3 mutations, although less frequent in CBF leukemia, but may result in sensitivity to inhibition by kinase inhibitors such as midastaurin, quizartinib or ruxolitinib, which, however, remains to be clinically investigated [81,82].